Merck (MRK) Announces FDA Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection
Go back to Merck (MRK) Announces FDA Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection| Merck & Co. (NYSE: MRK) | Delayed: 149.54 -3.56 (2.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $153.10 | 52 Week High | $65.46 | |||
| Open | $149.53 | 52 Week Low | $47.97 | |||
| Day High | $152.08 | P/E | 101.73 | |||
| Day Low | $149.02 | EPS | $1.47 | |||
| Volume | 8,528,140 | |||||

